Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Paediatrics
  4. Back
  5. Emergency Medicine (Paediatric)
  6. Adrenal insufficiency in children, emergency and acute management guidance, paediatrics (239)
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Adrenal insufficiency in children, emergency and acute management guidance, paediatrics (239)

Warning

Objectives

Standardisation of the emergency management of acutely unwell children with known or suspected adrenal insufficiency.

Scope

This clinical guidance should be used in children with known or suspected adrenal insufficiency who present acutely unwell.

Conditions: 

Children on daily replacement hydrocortisone treatment, eg.

  • Congenital Adrenal Hyperplasia
  • Congenital Adrenal Hypoplasia
  • Addison’s disease
  • Hypopituitarism eg congenital, brain tumour and post-radiotherapy

Children on high dose glucocorticoid treatment (Prednisolone, Deflazacort, Dexamethasone, Vamorolone) eg Inflammatory conditions like inflammatory arthritis, inflammatory bowel disease, Duchenne muscular dystrophy.

Source for guidance

This clinical guidance adopts recommendations from the UK National Paediatric Adrenal Insufficiency Emergency Management Guidance developed by the British Society for Paediatric Endocrinology and Diabetes (2022). The British Society for Paediatric Endocrinology and Diabetes guidance has also been incorporated into the NICE guideline [NG243] Adrenal insufficiency: Identification and management (Published 28th August 2024).

EMERGENCY MANAGEMENT OF SUSPECTED ADRENAL CRISIS (SEVERE ILLNESS OR STRESS): REQUIRE IM OR IV HYDROCORTISONE

Need for IM or IV hydrocortisone.

DO NOT DELAY ADMINISTRATION OF IM or IV HYDROCORTISONE WITH SUSPECTED ADRENAL CRISIS.  PATIENTS WITH SUSPECTED ADRENAL CRISIS COULD DETERIORATE RAPIDLY EVEN IF APPEAR WELL.

INITIAL MANAGEMENT OF SUSPECTED ADRENAL CRISIS

  • Administer IV bolus or IM hydrocortisone
  • Manage acute presentation as appropriate (treat the underlying cause)

IM or initial IV bolus hydrocortisone doses for suspected adrenal crisis

Age

Dose of hydrocortisone (IM or initial IV bolus)

Less than 1 year

25 mg

1 to 5 years

50 mg

6 years and over

100 mg

Indications:

  • Acutely unwell with diarrhoea and vomiting
  • Reduced responsiveness or loss of consciousness
  • Hypoglycaemia or new onset seizure in known or suspected adrenal insufficiency
  • Painful fracture or fractures with significant deformity
  • Significant burn
  • Major trauma or severe shock (eg road traffic accident, head injury with loss of consciousness

On arrival to hospital, check blood glucose as soon as possible.
If blood glucose < 3 mmol/L, give 3 ml/kg of 10% dextrose as bolus.
Recheck blood glucose in 15 min and repeat bolus if necessary.

If shock or moderate to severe dehydration, give 10 ml/kg of 0.9% sodium chloride and repeat if necessary.
Check electrolytes at presentation to inform fluid usage.

SUBSEQUENT MANAGEMENT OF SUSPECTED ADRENAL CRISIS

Following bolus of IV/IM hydrocortisone the child should be started on a hydrocortisone infusion

Hydrocortisone infusion for acute illness

Weight

Total dose in 24 hours

Infusion rate
(50mg hydrocortisone in 50ml 0.9% sodium chloride)

≤10kg

25 mg

1 ml/hr

10.1 to 20kg

50 mg

2 ml/hr

20.1 to 40kg

100 mg

4 ml/hr

40.1 to 70kg

150 mg

6 ml/hr

Over 70kg

200 mg

8 ml/hr

To make up hydrocortisone infusion

  • Add 50 mg hydrocortisone in 50 ml 0.9% sodium chloride
  • Hydrocortisone infusion can run alongside 0.9% sodium chloride or 5% glucose or PlasmaLyte solutions
  • Consider more concentrated infusions in those needing fluid restriction (eg 100 mg hydrocortisone in 50 ml 0.9% sodium chloride)

Maintenance fluid type

0.9% sodium chloride / 5 % glucose is usually an appropriate starting point.

Hyperkalaemia: Children with primary adrenal insufficiency can be hyperkalaemic at presentation or in an adrenal crisis because of mineralocorticoid deficiency. Emergency management of adrenal crisis with IV glucocorticoids and IV fluids (0.9% sodium chloride) will reduce potassium levels. Hyperkalaemia is potentially life-threatening and can lead to cardiac arrhythmias. Additional measures such as the use of IV calcium gluconate, nebulised salbutamol, IV insulin and glucose or IV bicarbonate and cation exchange resins should also be considered. 23

Hyponatraemia and fluids: Sodium chloride 0.9%/5% glucose is usually a good starting point for initial fluid management if the clinical and biochemical picture suggest that the low sodium has arisen primarily because of salt wasting.

  • In primary adrenal insufficiency (eg Addison’s disease, Congenital adrenal hyperplasia), mineralocorticoid deficiency will cause hyponatraemia due to renal losses.
  • In secondary adrenal insufficiency (eg hypopituitarism, patients with brain tumours or post-radiotherapy, patients on long term treatment dose of glucocorticoid eg Prednisolone, Deflazacort, Dexamethasone), cortisol deficiency can lead to a lack of free water clearance which can contribute to hyponatraemia. In this latter scenario (those with secondary adrenal insufficiency), a degree of fluid restriction may be more appropriate.

Fludrocortisone is an oral mineralocorticoid used in primary adrenal insufficiency. The dose does not need adjustment in the event of a sick day episode or an adrenal crisis. If the child is unable to take oral medication then IV fluids may be required to maintain the salt and water balance depending on the clinical situation. However, the mineralocorticoid effect of hydrocortisone at stress doses is often sufficient to cover the mineralocorticoid requirement. Oral fludrocortisone should be re-commenced when able to tolerate oral medication.

EMERGENCY MANAGEMENT OF SICK DAY EPISODE (MODERATE ILLNESS OR STRESS): REQUIRE ORAL SICK DAY DOSING

Need for oral sick day dosing

Indications:

  • Acute infections/childhood illnesses with fever (usually not well enough to go to school)
  • Vomiting or diarrhoea (only if tolerating oral medication and fluid but low threshold for consideration for IM or IV therapy)

Oral sick day dosing based on weight.

A guide to sick day dosing that can safely be used in the emergency setting is provided below. However, the actual dose may vary depending on the strength and preparation of the available hydrocortisone medication. Rounding up to the next 0.5 mg dosing is appropriate. Sick day dosing should be given for the duration of the illness. Patients own personalized sick day dosing plans from clinical review within the last 6 months (if available) can also be used.

Patients should should be advised to ring primary medical team if no improvement after 48 hours or if further deterioration on oral sick day dosing following discharge from the hospital/A&E.

For patients on treatment dose of glucocorticoid (eg Prednisolone, Deflazacort), a simple and safe approach is for additional sick day hydrocortisone to ensure adequate plasma cortisol levels throughout the day and night, on top of usual treatment dose of glucocorticoid (eg Prednisolone, Deflazacort). This is relevant as the half-life of Deflazacort is 1.5 to 1.9 hours; and the half-life of Prednisolone is 2.0 to 4.0 hours. The treatment dose of glucocorticoid (eg Prednisolone, Deflazacort) does not need to be altered during sick day episodes.

Weight(kg)

Sick day hydrocortisone:
Dose

Frequency

1

0.8 mg

4 x a day

2

1.2 mg

4 x a day

3

1.5 mg

4 x a day

4

2.0 mg

4 x a day

5

2.5 mg

4 x a day

6

2.5 mg

4 x a day

7

3.0 mg

4 x a day

8

3.0 mg

4 x a day

9

3.5 mg

4 x a day

10

4.0 mg

4 x a day

15

5.0 mg

4 x a day

20

6.0 mg

4 x a day

25

7.5 mg

4 x a day

30

7.5 mg

4 x a day

35

10.0 mg

4 x a day

40

10.0 mg

4 x a day

45

10.0 mg

4 x a day

50

10.0 mg

4 x a day

55

12.5 mg

4 x a day

60

12.5 mg

4 x a day

65

12.5 mg

4 x a day

70

15.0 mg

4 x a day

75

15.0 mg

4 x a day

80

15.0 mg

4 x a day

90

15.0 mg

4 x a day

EMERGENCY MANAGEMENT OF SICK DAY EPISODE (MILD ILLNESS OR STRESS): NO NEED FOR SICK DAY DOSING

No need for sick day dosing (ie no change to usual treatment)

Indications:

  • Mild cold or runny nose with no fever.
  • Minor playground bumps and bruises